Endovascular Treatment of Thoracic Aortic Disease

A trial with no phase registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 170 participants.

Also called NCT00583817

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 170 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT00583817
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT00583817. Non-randomized; no masking; primary purpose treatment. Start 2018-10-25 (actual); primary completion 2030-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Endovascular Treatment of Thoracic Aortic Disease
Acronym
EVOLVE Aorta
Condition
Thoracic Aortic Aneurysms
Condition
Dissecting, Aneurysm
Condition
Ascending Aorta Aneurysm
Condition
Aortic Arch; Aneurysm, Dissecting
Condition
Ascending Aortic Dissection
Condition
Thoracoabdominal Aortic Aneurysm
Condition
Renal Artery Aneurysm
Condition
Superior Mesenteric Artery Aneurysm
Condition
Aortic Dissection
Intervention (Device)
Endovascular stent-graft implantation
Lead sponsor
Matthew Eagleton (class: other)
Collaborator
Massachusetts General Hospital (class: other)

Record details

Record id
cardio:ct-nct00583817
Content hash
459772e9ec08a9fde90c6d69c9f9a1dd621510cb7dbd44d6ac3d1db7332fe190